Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases.

The glaucoma drug methazolamide removed tau build-up and lessened signs of dementia in genetically-engineered zebrafish and mice.

In this Q&A, Simon Lovestone, Vice President, Global Head, Neuroscience Discovery and Translational Science at Johnson & Johnson, shares how they are leveraging the A/T/N biomarker framework to ...

Researchers reveal that GPNMB could be an effective therapeutic agent to improve cardiac function and prevent heart failure. Researchers at the UCLA have identified the GPNMB protein (glycoprotein non ...

The self-assembly of human liver tissues in low Earth orbit could improve their differentiation and functionality. Tissue engineering and liver transplantation could be revolutionised following a ...

Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in ...

In this article, Dr Raminderpal Singh speaks to Janette Thomas of Five Alarm Bio for a biotech CEO’s perspective on the complexity of data faced by both large and small biotechs. Janette is on a ...